← News archive

Record check

Did the record support “US FDA extends review of Capricor's muscle disorder therapy by three months”?

Evidence state

developing

A dated primary-source record, attributable response, or correction that confirms, narrows, or resolves: US FDA extends review of Capricor's muscle disorder therapy by three months.

Receipts

  1. captured headline

    US FDA extends review of Capricor's muscle disorder therapy by three months

This page is a source-linked record. It does not score a person, infer motive, or replace the preserved source material.